Cited by 238Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis Research

Estimating the Number of Persons with Frontotemporal Lobar Degeneration in the US Population

Open access
Knopman, David S., Roberts, Rosebud O.·2011·Journal of Molecular Neuroscience

Abstract

There are many challenges for determining the prevalence and incidence of frontotemporal lobar degenerations (FTLD). Consequently, the number of cases of behavioral variant frontotemporal dementia (bvFTD) or primary progressive aphasia (PPA) in the USA is unknown. Our objective was to derive a consensus estimate of bvFTD and PPA prevalence and thereby to estimate the total number of these syndromes in the USA. We identified five prevalence and three incidence studies of FTLD based on passive surveillance and seven studies of survival in FTLD. Data from these studies were used to estimate the number of cases of PPA or bvFTD in the USA. Because prevalence and incidence estimates outside of the 45-64-year age range were either not available or widely divergent, we used data from clinical and pathological series to estimate the proportion of FTLD cases aged <45 or >64 years. The prevalence estimates in the age categories of 45-64 years old have ranged from 15 to 22 per 100,000 person-years in studies where both bvFTD and PPA were identified. The incidence estimates for the same age group ranged from 2.7 to 4.1 per 100,000 person-years. Using a survival rate of 6 to 9 years from onset and rates from the incidence studies, a calculated prevalence estimate (prevalence = incidence × duration) was similar to the previously reported prevalence rates. We estimated that 10% of cases were less than age 45 years and 30% were 65 years and older. We estimate that there are approximately 20,000 to 30,000 cases of the cognitive syndromes of FTLD in the USA. The main threat to the accuracy of the estimates is the difficulty in diagnosing the clinical syndromes that comprise the FTLD group of disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12031-011-9538-y

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 32 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Knopman, D. S., & Roberts, R. O.
Affiliations
Mayo Clinic (US)
Corresponding author
Knopman, David S.
Venue
Journal of Molecular Neuroscience
Published
2011-05-17
Volume
45
Issue
3
Pages
330-335
ISSN
  • 0895-8696 (ISSN-L)
  • 1559-1166
OpenAlex
W2074608237
Cited by
236
References
32
Citations by year
2026: 8 · 2025: 14 · 2024: 17 · 2023: 19 · 2022: 22 · 2021: 24 · 2020: 20 · 2019: 19 · 2018: 8 · 2017: 24 · 2016: 14 · 2015: 14 · 2014: 14 · 2013: 14 · 2012: 4
FWCI
7.22
Type
journal article
Language
en
Open access
Locations
  • Journal of Molecular Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Abbott Laboratories
  • Eli Lilly and Company
  • National Institutes of Health
  • National Institute on Aging (P50‐AG16574, U01AG06786, U01AG006786, R01AG023195, P50AG016574)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
frontotemporal lobar degeneration, behavioral variant frontotemporal dementia, primary progressive aphasia, prevalence estimation, incidence estimation, age distribution of cases, United States
MeSH terms
Adult, Aged, Humans, Middle Aged, United States, Cohort Studies, Survival Rate, Aphasia, Primary Progressive, Frontotemporal Lobar Degeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review